Please assess the completion status of the following clinical trial:

Trial Title: Post Hematopoietic Stem Cell Transplantation

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria~* Patients who had hematopoietic stem cell transplantation (HSCT) for beta-thalassemia major~* hematopoietic stem cell transplantation (HSCT) was performed minimum 6 months and maximum 2 years ago~* The washout period after the immunosuppressive therapy should be at least 3 months.~* Signifacant IOL should be present including:~A. Serum ferritin \>1000 μg/L or B. cardiac MRI \<20 ms or C. liver iron concentration ≥ 5 mg/g dry weight measured by R2\* MRI~Exclusion Criteria~* Patients who had any contraindication for treatment with deferasirox according to the prescribing information~  •Patients who depended on transfusion~* Patients with clinical symptoms of cardiac dysfunction (shortness of breath at rest or exertion, orthopnea, exercise intolerance, lower extremity edema, arrhythmias)~* Patients who were experiencing severe complication of HSCT e.g. acute Graft-versus host disease (GVHD)~* Significant proteinuria / Increase in serum creatinine

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- ICL670 (Type: EXPERIMENTAL): Oral dose of ICL670 at 10 mg/kg daily

Based on this trial design, predict the completion outcome and termination type (if applicable).